Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
muscle function
Biotech
Chasing Big Pharma rivals, NMD posts data on rare disease drug
NMD thinks its drug may improve health issues that therapies from AstraZeneca, argenx, Johnson & Johnson and UCB are unable to address.
Nick Paul Taylor
Oct 11, 2022 6:48am
Aeon hits phase 2 goals in rare disorder
Sep 23, 2022 11:30am
Astellas quietly cuts $450M-plus Cytokinetics R&D pact
May 3, 2021 7:15am
Dyne Therapeutics gunning for $100M IPO weeks after a VC raise
Aug 26, 2020 7:55am
Fulcrum's losmapimod fails muscle wasting interim analysis
Aug 11, 2020 9:06am
Avidity nets $100M to bankroll muscle disorder pipeline
Nov 13, 2019 4:00pm